Mechanism of Drug Resistance to First‐Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas
Cancer Reports · 2024
DOI: 10.1002/cnr2.70033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Chenggong Zeng und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Neuroblastoma, Drug Resistance, Neoplasm, Beclin-1, Apoptosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Background
The prognosis of high‐risk neuroblastomas (NB) that are resistant to first‐line induction chemotherapy is relatively poor. This study explored the mechanism of resistance to first‐line chemotherapeutics mediated by TXNDC17 and its potential solutions in NB.
Methods
The genetic and clinical data of patients with NB were obtained from the Therapeutically Applicable Research to Generate Effective Treatments dataset. TXNDC17 and BECN1 expressions in NB cells were up‐ and downregulated by transfection with plasmids and shRNA, respectively. Autophagy‐related proteins were detected by western blot. Cell viability was determined using cell proliferation and toxicity experiments. Apoptotic cells were detected using flow cytometry.
Results
Overall, 1076 pediatric and adolescent patients with NB were enrolled in this study. The 10‐year overall survival (OS) rates and event‐free survival (EFS) rates for the patients with a mutation of BECN1 were 37.4 ± 9.1% and 34.5 ± 8.8%, respectively. For patients with a mutation of TXNDC17, the 10‐year OS and EFS were 41.4 ± 5.9% and 24.3 ± 5.1%, respectively, which were significantly lower than those in the unaltered group. The overexpression of BECN1 and TXNDC17 reduced NB sensitivity to cisplatin (DDP), etoposide (VP16), and cyclophosphamide (CTX). Autophagy mediated by BECN1 was regulated by TXNDC17, and this process was involved in the resistance to DDP, VP16, and CTX in NB. Suberoylanilide hydroxamic acid (SAHA) can enhance the sensitivity and apoptosis of NB cells to chemotherapeutics by inhibiting TXNDC17, ultimately decreasing autophagy‐mediated chemoresistance.
Conclusions
Acquired resistance to first‐line chemotherapeutics was associated with autophagy mediated by BECN1 and regulated by TXNDC17, which can be reversed by SAHA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, PR China.
- Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, PR China.
- Department of Pediatric Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, PR China.
ORCID-Profile: Chenggong Zeng
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Zeng, C., Li, Z., Wei, Z., Chen, T., Wang, J., Huang, J., Sun, F., Zhu, J., Lu, S., & Zhen, Z. (2024). Mechanism of Drug Resistance to First‐Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas. Cancer Reports. https://doi.org/10.1002/cnr2.70033
Vancouver
Zeng C, Li Z, Wei Z, Chen T, Wang J, Huang J, et al. Mechanism of Drug Resistance to First‐Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas. Cancer Reports. 2024. doi:10.1002/cnr2.70033
BibTeX
@article{Zeng2024,
author = {Zeng, Chenggong and Li, Zhuoran and Wei, Zhiqing and Chen, Tingting and Wang, Juan and Huang, Junting and Sun, Feifei and Zhu, Jia and Lu, Suying and Zhen, Zijun},
title = {Mechanism of Drug Resistance to First‐Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.70033}
}
EUVIMED